29 results about "Intravenous use" patented technology

1. Name of the product in this design: Intravenous drip sensor (rechargeable). 2. Purpose of this design: For use as a vein drip sensor. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

To provide a therapeutic and / or prophylactic agent for mycosis, which is excellent in safety and effectiveness, is administered to a Japanese mycosis patient, and contains isavuconazole or a prodrug thereof as an active ingredient.SOLUTION: A therapeutic and / or prophylactic agent for mycosis, which is administered according to a loading dosing regimen, and further administered according to a maintenance dosing regimen after a lapse of 12 to 24 hours from the end of the loading dosing regimen. (1) Loading dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion every 8 hours for a total of 6 times (2) Maintenance dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion once a day in terms of isavuconazole per dose.SELECTED DRAWING: Figure 1

The article to which this design pertains is an arm cover. This article (arm cover) is used to prevent hospitalized patients from removing their intravenous drips.

The utility model discloses an outdoor outpatient service trolley, and belongs to the technical field of trolleys. Comprising a trolley carrying plate, a protection frame is arranged at the top end of the trolley carrying plate and used for protecting a child, an adjusting mechanism is arranged on one side of the top end of the trolley carrying plate and used for adjusting the use height of an infusion bottle frame, and a locking assembly is arranged on one side of a second side plate and used for locking the infusion bottle frame. The locking assembly is used for locking the height of the adjusted infusion bottle frame, through the arrangement of the adjusting mechanism and the protection frame, the protection frame can provide a lying space for a child, the child can have a rest for infusion conveniently, the adjusting mechanism can adjust the height of an infusion bottle, the infusion bottle can be better placed conveniently, the adjusting mechanism can be folded when the infusion bottle frame is not used, and use of the trolley is not affected.

The disclosure is directed to an aseptic, ready-to-use, premixed liquid pharmaceutical composition having sodium bicarbonate in a concentration of from about 0.05 mEq / mL to about 5 mEq / mL, carbon dioxide, and optionally one or more pharmaceutically acceptable excipients, the liquid pharmaceutical composition being packaged in a container for intravenous use, and the container including polyethylene terephthalate and SiOx. Also disclosed are method of making the an aseptic, ready-to-use, premixed liquid pharmaceutical compositions described herein.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a navel therapy composition and a navel therapy preparation for preventing and treating abdominal pain caused by intravenous drip of azithromycin in children and a preparation method of the navel therapy composition and the navel therapy preparation. The technical key points are as follows: the fructus evodiae and the dysentery are combined according to a specific weight ratio, and are matched with pharmaceutic adjuvants such as a transdermal enhancer and an excipient to prepare special navel therapy dosage forms such as pills, cakes, patches and the like. According to the composition, by utilizing the characteristics that the Shenque acupoint (navel) epidermal cuticle is thin, the barrier function is weak, blood vessels are rich, and medicines are easy to disperse and absorb, adverse reactions such as gastrointestinal spasmodic pain, nausea and vomiting and the like caused by intravenous drip of azithromycin in children are effectively relieved through an administration mode of external application. Through clinical verification, the umbilical therapy preparation can remarkably reduce the incidence rate and severity score of stomachache, vomiting and diarrhea, and remarkably improve the treatment compliance of child patients.

To provide a program that outputs symptom information regarding signs of self-removal of intravenous drip. [Solution] The program acquires time-series data regarding the movement of a second hand, different from the first hand being punctured, and outputs symptom information by inputting the acquired time-series data into a learning model that outputs symptom information regarding signs of self-removal of an IV drip when time-series data is input. Preferably, the program acquires video data of the puncture site and the movement of the second hand captured by a camera, and inputs the video data into the learning model to output the symptom information.

To provide improved, stable aspirin formulations for intravenous use, as well as applications thereof.SOLUTION: A lyophilized aspirin composition is provided, the composition comprising a lyophilized mixture of crystalline aspirin in the free acid form, a bulking agent, and a surfactant. Also provided is the use of the lyophilized aspirin composition in the manufacture of a medicament for aspirin therapy by intravenous administration to a mammal in need thereof, the manufacture comprising reconstituting the lyophilized aspirin composition with water comprising a basic agent in an amount sufficient to provide an aspirin solution having a pH of at least 5.5.SELECTED DRAWING: None

The invention belongs to the field of medicines, and provides a letemovir injection and a preparation method thereof, the letemovir injection is a high-concentration letemovir injection for intravenous drip, and the letemovir injection comprises letemovir, an alkaline reagent, a pH regulator, a buffer agent, a non-aqueous solvent for injection and water for injection. According to the injection, the solubility of letemovir is greatly improved, hydroxypropyl-beta-cyclodextrin is abandoned as a solubilizer in a prescription, so that accumulated toxicity of the kidney is avoided, and the injection prescription does not contain other known solubilizers and surfactants for pharmaceutical preparations, so that the medication safety is remarkably improved; the injection can tolerate thermocompression sterilization, no visible foreign matter exists in the sterilized solution and after compatibility, the adverse reaction risk caused by capillary obstruction is avoided or reduced, and the clinical medication safety is remarkably improved; the preparation process is simple, production amplification is easy to realize, and the method has great application value.

The present invention relates to a stable antibody formulation for intravenous use comprising: a. about 10-40 mg / mL nivolumab, b. about 20 mM L-histidine buffer, c. about 270 mM sucrose, d. about 0.02 % w / v polysorbate 80, and e. about 10 mM L-methionine. The antibody formulation is stable at about 2 °C to about 8 °C for about 12 months. The stable antibody formulation is for use in the treatment of cancer.

To provide a simple retainer that can retain a plurality of infusion tubes to a support body around a bed while juxtaposing the infusion tubes without any tangle.SOLUTION: A retainer 1 includes: a substrate 2 made of a substantially rectangular solid-shaped foam plastic; a reinforcement member 3 made of an elastic synthetic resin and fitted into the substrate and fixed to the substrate; and a fixing member 4 for holding the substrate 2 to a support body around a bed. The substrate 2 is made of a foam plastic and includes: a plurality of slits 21 for nipping an infusion tube 103; a plurality of guide grooves 22 for guiding insertion of the infusion tube 103 into the slit 21; a plurality of nipping parts 23 for elastically nipping the infusion tube 103 between both sides of the slit 21; and a notch 24 for fitting the reinforcement member 3. The fixing member 4 comprises first and second hook-and-loop fasteners 41, 42.SELECTED DRAWING: Figure 2

The item in question is an armrest that is standard equipment on stretchers used in hospitals and ambulances for transporting patients. The armrest is usually positioned vertically to narrow the width of the stretcher for transporting patients, but in some cases, blood transfusions and intravenous drips are administered. The armrest is opened horizontally, allowing the patient's arm to rest on the top surface. However, when the armrest on a typical stretcher is opened, the top surface is significantly lower than the mat, causing the patient's arm to hang at an angle, making intravenous drips difficult to administer. This armrest has a double structure with an upper and lower panel overlapping each other. Two fixing pins on the lower panel are inserted into the stretcher's pivot bosses to secure the armrest in place. Furthermore, when a lever located in the gap between the upper and lower panels is rotated, the upper panel rises significantly via a link. The lever rotates in an arc, and as can be seen in the plan view, the lever grip does not protrude outward at either the right or left extreme positions. When the lever is set to the right end, the arm rest becomes thinner, while when set to the left end, the top panel rises and becomes thicker, making IV administration easier. During normal transport, the arm rest is kept thin and vertically positioned so that it does not protrude to the side, resulting in no inconvenience. When an urgent transfusion or IV is required, the top panel of the arm rest rises with a single touch, saving time and allowing for quick preparation, a major advantage. While it is possible to place a cushion under the arm, the interior of an ambulance is often too narrow to store a cushion, and it can easily get lost. Having this arm rest as standard equipment eliminates this problem. Since transfusions and IVs are usually administered in the right arm, this arm rest only needs to be standard equipment on the right side.

This product is a hollow, tubular tourniquet that is worn around the arm during blood collection, intravenous drips, etc., and has a flower-shaped cavity formed continuously in the longitudinal direction in the radial center. The cross section of the cavity is shaped like a flower, giving it a playful touch, and can help relieve tension for the user during blood collection, intravenous drips, etc.

The utility model relates to an equipment belt structure for an assembled ward. The equipment belt structure comprises a mounting unit, a main body unit, a locking unit, a hook unit and an adjusting unit, the connecting structure has the advantages that after the mounting unit is connected with the wall body, the mounting unit is connected with the main body unit in a clamping mode, traditional punching bolt fixing is replaced, damage to a prefabricated wall body structure is avoided, the integrity of the wall body and the advantages of a fabricated building are reserved, meanwhile, the mounting process is simplified, and the construction efficiency is improved; movement of the main body unit can be limited by the locking unit, loosening and displacement of the equipment belt caused by external force collision are avoided, and use safety is guaranteed. The hook unit is matched with the adjusting unit, so that the limitation that the hanging position of an infusion bottle is fixed is solved. The adjusting unit can flexibly adjust the transverse position of the hook unit according to the actual requirements of patients and the position change of the sickbed, the infusion requirements of different patients are met, and operation of medical staff is facilitated.

The application discloses a kind of oral sustained-release composition of edaravone, preparation method and application.The application provides a kind of pharmaceutical composition, it includes tablet core and coating;The tablet core includes drug-containing layer tablet core and / or boost layer tablet core;The drug-containing layer tablet core includes edaravone pharmaceutical active ingredient and carrier;The carrier is one or more in polymer carrier, osmotic pressure regulator, swelling agent, thickening agent and lubricant;The boost layer tablet core includes one or more in osmotic pressure regulator, swelling agent, colorant and lubricant.The pharmaceutical composition of the application maintains 24 hours sustained-release, oral convenient, blood drug concentration is stable, avoids the method of 2 times intravenous drip in a day, improves patient compliance.In addition, the pharmaceutical composition, prescription and preparation process are simple, easy to industrial production.

The invention discloses an application of a pharmaceutical composition in preparation of a medicine for promoting blood circulation to remove blood stasis, and relates to the technical field of traditional Chinese medicine compound preparations, the pharmaceutical composition comprises the following seven components: a Xuesaitong injection, a ginkgo dipyridamole injection, a salvia miltiorrhiza injection, an astragalus membranaceus injection, a blood pricking and bloodletting device, a Xiaoyao pill oral preparation and a pulse-activating decoction oral liquid; the application method comprises the following steps: sequentially carrying out intravenous drip injection of the Xuesaitong injection, the Ginkgo damole injection and intravenous drip of the Salvia miltiorrhiza injection; then a blood pricking and bloodletting device is used for cooperating operation; and then, carrying out intravenous drip of the astragalus membranaceus injection for administration. After injection, the Xiaoyao pills and the pulse-activating decoction are orally taken; through intravenous injection, blood pricking therapy and oral consolidated drug action paths, a new application way of the pharmaceutical composition in the blood circulation promoting and blood stasis removing drugs is provided, clear sequential use of the blood circulation promoting and blood stasis removing pharmaceutical composition is achieved, the purposes of rapid blood circulation promoting and blood stasis removing and long-acting physique conditioning of the pharmaceutical composition are achieved, and the pharmaceutical composition is safe and efficient.

The disclosed invention relates to a wearable intravenous drip device comprising: a first plate; at least one static load spring mounted on the first plate; a second plate to which a free end of a leaf spring wound around a drum of the static load spring is fixed, and which is disposed to face the first plate; and an upper arm loading part coupled to the second plate, wherein the static load springs apply elastic force causing a relative extension / contraction movement to be generated with respect to the first plate and the second plate, and the elastic force of the static load springs is constant regardless of the displacement of the leaf spring.

The article to which this design pertains is an arm cover. This article (arm cover) is used to prevent hospitalized patients from removing their intravenous drips.

This product is a hollow, tubular tourniquet that is worn around the arm during blood collection, intravenous drips, etc., and has a flower-shaped cavity formed continuously in the longitudinal direction in the radial center. The cross section of the cavity is shaped like a flower, giving it a playful touch, and can help relieve tension for the user during blood collection, intravenous drips, etc.

This product is a hollow, tubular tourniquet that is worn around the arm during blood collection, intravenous drips, etc., and has a cavity in the shape of an animal running continuously along the length of the radial center. The cross section of the cavity is shaped like an animal, giving it a playful touch, and it can help relieve tension for the user during blood collection, intravenous drips, etc.

The present application discloses a composition for treating painful disc injury syndrome (PDDS), disc bulging, disc herniation, and disc herniation, as well as a delivery method and recommended treatment regimen for delivering an effective dose of the composition to a patient. The composition has the characteristics of inflammation resistance, oxidation resistance, vasodilation and spasmolysis. The composition is administered by intravenous drip over a specific period of time to relieve pain.

The invention relates to the technical field of intravenous therapy data tracking, in particular to an intravenous therapy information data tracking method, system and equipment, and the method comprises the steps: determining an information effective factor of each moment in each time period of each patient; according to the difference between the intravenous drip speed at each moment in each time period and the intravenous drip speed in the neighborhood of each time period, in combination with the information effective factor, determining an intravenous therapy characteristic factor of each patient at each moment in each time period; according to the difference between the feature vectors of all data tracking moments of each patient in any time period and the feature vectors of all data tracking moments of other patients in any time period in the same type of disease group, vein treatment data of the patients are tracked. According to the method, the related data in the vein treatment process is comprehensively analyzed, the vein treatment similarity between the patients in the same type of disease group is determined, the accuracy of effective information extraction is improved, and the credibility of the vein treatment related data is enhanced.

The present invention provides a method of treating CD20 positive B cell lymphoma with Usutuzumab, involving the rate of administration of Usutuzumab. In some embodiments, the methods comprise an intravenous drip infusion at 1000 mg of ustuzumab olbabine each administration, and are administered in two or more cycles at a specific administration rate.

The utility model relates to a hospital gown, in particular to a predelivery hospital gown which is convenient for pregnant and lying-in women to put on, take off, replace and clean and is convenient for medical personnel to examine and operate. The shoulders of the hospital gown are opened and closed through the snap fasteners I and can be matched with the snap fasteners II on the front part, and the hospital gown can be directly replaced without hand intravenous drip. The detachable lower hem and the standby lower hem are arranged below the back and replaced at any time when polluted, and the puerpera is kept clean and comfortable. The rear waist part fixes a fetal heart monitor bandage through a waist loop, and bandage sub-bands branched from the two ends of the rear waist part can fix a fetal heart monitoring probe and a uterine contraction pressure probe respectively to prevent the fetal heart monitoring probe and the uterine contraction pressure probe from falling off and are convenient to store. The whole hospital gown is in an A shape, side openings are formed in the two sides of the lower portion, pulling belts are arranged on the shoulders on the two sides and used for clamping and hanging an analgesia pump, a pocket is arranged in front of the chest, no collar is arranged on the upper side, and cuffs are arranged on the shoulders. The predelivery hospital gown is high in practicability, can improve comfort and dignity of pregnant and lying-in women, reduces interference and infection risks, facilitates medical care operation and has good clinical application value.

An object of the present invention is to provide an injection solution for boron neutron capture therapy. Provided is an injection solution for boron neutron capture therapy, containing p-boronophenylalanine or a pharmaceutically acceptable salt thereof, with a ratio of boron 10 of boron atoms in a compound of 75% or more; a sugar alcohol; an antioxidant; and water, the injection solution having a pH of 6.5 to 7.8 and an osmotic pressure ratio of 1.0 to 1.8, the injection solution being to be administered by intravenous drip injection.

The invention discloses a pharmaceutical composition containing a photosensitizer and an immune checkpoint inhibitor, each unit dose of the pharmaceutical composition contains 1-100mg of a photosensitive drug DTP and 1-100mg of a PD-L1 inhibitor, and the unit dose is the total amount of a pharmaceutical preparation used every day. The pharmaceutical composition containing the photosensitizer and the immune checkpoint inhibitor is prepared by mixing 1-100 mg of a photosensitive drug DTP and 1-100 mg of a PD-L1 inhibitor to prepare a liquid preparation for injection administration, such as freeze-dried powder injection, injection, large and small infusion or intravenous drip. The invention also provides an application of a pharmaceutical composition taking the photosensitive drug DTP and the PD-L1 inhibitor as active ingredients in preparation of antitumor drugs. The pharmaceutical composition taking the photosensitive drug DTP and the PD-L1 inhibitor as the active ingredients has a remarkable treatment effect in the anti-tumor aspect, not only has a good treatment effect on local tumors in photodynamic therapy, but also has a synergistic anti-cancer effect on far-end tumors. The combined application of photodynamic therapy and immunotherapy enhances respective curative effects, the photodynamic therapy provides instant cytotoxic effect, and the immunotherapy provides long-term capability of monitoring and removing residual tumor cells, so that the overall treatment efficiency is improved, and the risk of tumor recurrence and metastasis is reduced.

The invention discloses a preparation method and application of a cryopreservation solution supporting high-density clinical stem cells. The cryopreservation liquid is composed of normal saline injection, human serum albumin (HSA) for injection, glucose, dimethyl sulfoxide (DMSO) for injection, hydroxyethyl starch injection, dextran injection and the like. And the high-density clinical stem cell cryopreservation liquid is prepared through accurate proportioning under the sterile condition. The application method comprises the following steps: after collecting stem cells, re-suspending and uniformly mixing the stem cells with a cryopreservation solution pre-cooled to 4 DEG C, slowly cooling to-80 DEG C by a program, and then transferring the stem cells into liquid nitrogen for long-term preservation. During resuscitation, the temperature is rapidly increased to 37 DEG C, so that the cell cryopreservation liquid is rapidly thawed, and then the cell cryopreservation liquid is recovered to room temperature and can be directly used for clinical local injection or used for intravenous drip after being diluted by normal saline.

The invention discloses a pharmaceutical composition containing a photosensitizer and an autophagy inhibitor, each unit dose of the pharmaceutical composition contains 1-100mg of a photosensitive drug DTP and 6-600mg of an autophagy inhibitor chloroquine phosphate, and the unit dose is the total amount of a pharmaceutical preparation used every day. The pharmaceutical composition containing the photosensitizer and the autophagy inhibitor is prepared by mixing 1-100mg of a photosensitive drug DTP and 6-600mg of an autophagy inhibitor chloroquine phosphate to prepare a liquid preparation for injection administration, such as freeze-dried powder injection, injection, large and small infusion or intravenous drip. The invention also provides an application of a pharmaceutical composition taking the photosensitive drug DTP and the autophagy inhibitor chloroquine phosphate as active ingredients in preparation of antitumor drugs. The pharmaceutical composition taking the photosensitive drug DTP and the autophagy inhibitor chloroquine phosphate as the active ingredients has a remarkable treatment effect in the anti-tumor aspect, not only has a good treatment effect on local tumors of prostatic cancer, but also shows synergistic anti-tumor activity. Combined application of the photodynamic therapy and the autophagy inhibitor is a research hot spot in the field of tumor treatment, and the research trend focuses on improvement of the treatment effect and deep understanding of an interaction mechanism between the photodynamic therapy and cell autophagy, so that the photodynamic therapy and the autophagy inhibitor can be more effectively applied to clinical treatment.

The utility model provides an infusion alarm device, which relates to the technical field of infusion nursing and comprises a clamping mechanism, the clamping mechanism is provided with a handpiece, one end of the handpiece is provided with a clamping groove, and the inner side of the clamping groove is fixedly connected with an anti-falling pad. Due to the fact that the caliber of the bottle opening arranged on the medicine bottle body is mostly the limited caliber of the unified standard, in the medicine dispensing process of the medicine bottle body or the intravenous drip process of a patient, the spring piece and the push rod which are arranged in the clamping mechanism are matched with the sliding block to be in linkage with the groove position formed in the handheld piece. Therefore, the bottle opening formed in the medicine bottle body can be connected with the anti-falling pad and the clamping block which are arranged on the handheld piece in a clamped mode, in the process, operation can be carried out only by pushing the push rod by medical staff, and a patient can observe the injection dosage in the dispensing and intravenous drip process after clamping through the arranged alarm device body, so that the operation is convenient, and the working efficiency is improved. And the accuracy of medicament dosage during medicament dispensing is ensured.